Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
OSI Pharmaceuticals
This is a single-arm, phase 1b study to determine the maximum tolerated dose (MTD) of the combination of erlotinib (daily), gemcitabine (weekly), nab-paclitaxel (weekly) in patients with advanced pancreatic cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
Predicted life expectancy of \>= 12 weeks
Previous surgery
Histologically or cytologically confirmed, measurable, locally advanced, unresectable or metastatic pancreatic adenocarcinoma
No prior therapy for pancreatic cancer
Adequate organ and marrow function
* Absolute neutrophil count \>= 1.5 x 10\^9/L
* Platelets \>= 100 x 10\^9/L
* Total bilirubin \<= institutional upper limits of normal
* AST (SGOT)/ALT(SGPT) \<= 2 x institutional upper limits of normal
* Serum creatinine \<= 1.5 x upper limits of normal
Negative pregnancy test
Informed consent
Patient must agree not to smoke while on study
You may not be if
Significant history of cardiac disease unless the disease is well controlled
Active or uncontrolled infections or serious illness or medical conditions that could interfere with the patient's ongoing participation in study
History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent
History of smoking within the previous 14 days before enrollment or positive cotinine test at baseline
Pregnant or breast-feeding females
Symptomatic brain metastases that are not stable, that require steroids, that are potentially life-threatening, or that have required radiation within the last 14 days
History of allergic reactions attributed to compounds of similar chemical or biological composition to the study drugs
